Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States.
It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.
It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays.
The company was incorporated in 1998 and is headquartered in Menlo Park, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 1, 24 | 0.25 Increased by +78.57% | 0.22 Increased by +13.64% |
| Feb 15, 24 | 0.28 Increased by +100.00% | 0.26 Increased by +7.69% |
| Nov 1, 23 | 0.28 Decreased by -6.67% | 0.22 Increased by +27.27% |
| Aug 2, 23 | 0.25 Increased by +4.17% | 0.15 Increased by +66.67% |
| May 3, 23 | 0.14 Decreased by -30.00% | 0.19 Decreased by -26.32% |
| Feb 28, 23 | 0.14 Decreased by -46.15% | 0.23 Decreased by -39.13% |
| Nov 3, 22 | 0.30 Increased by +25.00% | 0.23 Increased by +30.43% |
| Aug 3, 22 | 0.24 Increased by +14.29% | 0.24 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 123.60 M Increased by +21.50% | 31.38 M Decreased by -9.33% | Increased by +25.39% Decreased by -25.38% |
| Jun 30, 23 | 117.72 M Increased by +13.86% | 27.53 M Increased by +0.42% | Increased by +23.39% Decreased by -11.80% |
| Mar 31, 23 | 105.65 M Increased by +12.77% | 15.88 M Decreased by -30.35% | Increased by +15.03% Decreased by -38.23% |
| Dec 31, 22 | 103.06 M Increased by +4.28% | 16.60 M Decreased by -48.21% | Increased by +16.11% Decreased by -50.34% |
| Sep 30, 22 | 101.73 M Increased by +5.82% | 34.61 M Increased by +13.58% | Increased by +34.02% Increased by +7.33% |
| Jun 30, 22 | 103.39 M Increased by +12.88% | 27.41 M Increased by +3.35% | Increased by +26.51% Decreased by -8.44% |
| Mar 31, 22 | 93.69 M Increased by +17.94% | 22.80 M Decreased by -2.85% | Increased by +24.33% Decreased by -17.62% |
| Dec 31, 21 | 98.82 M Increased by +15.26% | 32.05 M Increased by +23.31% | Increased by +32.44% Increased by +6.98% |